Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

ABK0007

Sigma-Aldrich

HercBridge ELISA Kit

Sinonimo/i:

Protein Conformational Array Herceptin Biosimilar, Protein Conformational Array Trastuzumab

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Codice UNSPSC:
41116158
NACRES:
NA.32

Forma dell’anticorpo

IgG fraction of antiserum

Reattività contro le specie

human (Human IgG)

Condizioni di spedizione

wet ice

Temperatura di conservazione

2-8°C

Descrizione generale

A Protein Conformational Array (PCA) in a sandwich ELISA format where the plate is coated with a panel of antibodies raised against peptides derived from the full length protein sequence of Trastuzumab. Taken individually, each of these antibodies is strongly antigenic to the peptide sequence that was used in its production. However, when these peptides are incorporated into a full length correctly folded protein, the antigenicity of many of them is masked by the three dimensional structure of the protein and only a limited number of the antibodies respond. The result is a histogram which can be likened to a ‘fingerprint′ for correctly folded Trastuzumab. For a Herceptin Biosimilar, if the protein is correctly folded and glycosylated, the ‘fingerprint′ will match that of Trastuzumab. If it is not correctly folded, previously masked peptide sequences will be exposed and will be recognized by the antibody made to that exposed sequence. In this way, changes in the ‘fingerprint′ generated by the ELISA will point out differences between the Biosimilar and authentic Trastuzumab.

Applicazioni

For research use only. Not for use in diagnostic procedures.

Pittogrammi

Corrosion
GHS05

Avvertenze

Warning

Indicazioni di pericolo

H290,H315,H319

Classi di pericolo

Eye Irrit. 2 - Met. Corr. 1 - Skin Irrit. 2

Codice della classe di stoccaggio

8A - Combustible corrosive hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 1

Elenchi normativi

Forniamo informazioni su eventuali restrizioni prevalentemente per i prodotti chimici. Per altre tipologie di prodotto siamo in grado di fornire soltanto informazioni limitate. Nessuna segnalazione significa che nessuno dei componenti è citato in un elenco. È dovere dell’utilizzatore assicurarsi che il prodotto venga impiegato in maniera sicura e a norme di legge.

EU REACH Annex XVII (Restriction List)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Jihun Lee et al.
mAbs, 10(4), 547-571 (2018-02-28)
The evaluation of analytical similarity has been a challenging issue for the biosimilar industry because the number of lots for reference and biosimilar products available at the time of development are limited, whilst measurable quality attributes of target molecule are
Xing Wang et al.
Frontiers in pharmacology, 4, 103-103 (2013-08-24)
Antibody arrays were developed to probe a monoclonal antibody's three-dimensional structure (3-D structure). Peptides with overlapping regions were designed to cover the whole mAb light chain and heavy chain, respectively, and used to generate polyclonal antibodies after the conjugation of
Yuanli Song et al.
mAbs, 10(3), 397-405 (2018-01-10)
The elucidation of antibody higher order structure (HOS) is critical in therapeutic antibody development. Since HOS determines the protein bioactivity and chemo-physical properties, this knowledge can help to ensure that the safety and efficacy attributes are not compromised. Protein conformational
Biosimilar mAb in-process Sample Higher Order Structure Analysis with Protein Conformational Array ELISA.
Michael Davies, Gan Wang, Jian Gong, Guofeng Fu and Xing Wang
Pharmaceut. Res., 1-11 (2016)
Soon Kwan Jung et al.
mAbs, 6(5), 1163-1177 (2014-12-18)
Remsima (infliximab) was recently approved as the world's first biosimilar monoclonal antibody (mAb) in both the European Union and Korea. To achieve this, extensive physicochemical characterization of Remsima in relation to Remicade was conducted in order to demonstrate the highly

Articoli

Protein Conformation Array Multiplexing

Monoclonal antibodies (mAbs) are the fastest growing class of human therapeutics within the field of biologics, having predicted worldwide sales of $125 billion by 2020 based on current approval rates.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.